Single-shot bevacizumab for cerebral radiation injury
Open Access
- 17 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 21 (1), 1-7
- https://doi.org/10.1186/s12883-021-02103-0
Abstract
Cerebral radiation injury, including subacute radiation reactions and later stage radiation necrosis, is a severe side effect of brain tumor radiotherapy. A protocol of four infusions of the monoclonal antibody bevacizumab has been shown to be a highly effective treatment. However, bevacizumab is costly and can cause severe complications including thrombosis, bleeding and gastrointestinal perforations. We performed a retrospective analysis of patients treated in our clinic for cerebral radiation injury who received only a singular treatment with bevacizumab. Single-shot was defined as a singular administration of bevacizumab without a second administration during an interval of at least 6 weeks. We identified 11 patients who had received a singular administration of bevacizumab to treat cerebral radiation injury. Prior radiation had been administered to treat gliomas (ten patients) or breast cancer brain metastases (one patient). 9 of 10 patients with available MRIs showed a marked reduction of edema at first follow-up. Discontinuation of Dexamethasone was possible in 6 patients and a significant dose reduction could be achieved in all other patients. One patient developed pulmonary artery embolism 2 months after bevacizumab administration. The median time to treatment failure of any cause was 3 months. Single-shot bevacizumab therefore has meaningful activity in cerebral radiation injury, but durable control is rarely achieved. In patients where a complete protocol of four infusions with bevacizumab is not feasible due to medical contraindications or lack of reimbursement, single-shot bevacizumab treatment may be considered.This publication has 23 references indexed in Scilit:
- Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of SurvivalYonsei Medical Journal, 2018
- Survival and complications of stereotactic radiosurgeryMedicine, 2017
- Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscapeJournal of Neuro-Oncology, 2017
- Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastomaNeuro-Oncology, 2016
- Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialJournal of Clinical Oncology, 2016
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous SystemInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer PatientsJAMA, 2008
- Hypoxia and Hypoxia-Inducible Factor-1 Target Genes in Central Nervous System Radiation InjuryClinical Cancer Research, 2004